These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 12447918

  • 1. Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands.
    El-Subbagh H, Wittig T, Decker M, Elz S, Nieger M, Lehmann J.
    Arch Pharm (Weinheim); 2002 Nov; 335(9):443-8. PubMed ID: 12447918
    [Abstract] [Full Text] [Related]

  • 2. Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
    Enzensperger C, Kilian S, Ackermann M, Koch A, Kelch K, Lehmann J.
    Bioorg Med Chem Lett; 2007 Mar 01; 17(5):1399-402. PubMed ID: 17188870
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dopamine receptor ligands. Part 18: (1) modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists.
    Robaa D, Enzensperger C, Abul Azm Sel D, El Khawass el S, El Sayed O, Lehmann J.
    J Med Chem; 2010 Mar 25; 53(6):2646-50. PubMed ID: 20180564
    [Abstract] [Full Text] [Related]

  • 6. Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding.
    Metwally KA, Dukat M, Egan CT, Smith C, DuPre A, Gauthier CB, Herrick-Davis K, Teitler M, Glennon RA.
    J Med Chem; 1998 Dec 03; 41(25):5084-93. PubMed ID: 9836624
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300.
    Rostom SA, Farghaly AM, Soliman FS, el-Semary MM, Elz S, Lehmann J.
    Arch Pharm (Weinheim); 2001 Jul 03; 334(7):241-7. PubMed ID: 11512275
    [Abstract] [Full Text] [Related]

  • 9. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
    Hamacher A, Weigt M, Wiese M, Hoefgen B, Lehmann J, Kassack MU.
    BMC Pharmacol; 2006 Sep 15; 6():11. PubMed ID: 16978403
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist.
    Kassack MU, Höfgen B, Decker M, Eckstein N, Lehmann J.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Dec 15; 366(6):543-50. PubMed ID: 12444495
    [Abstract] [Full Text] [Related]

  • 11. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH, Milhahn H, Eich E.
    J Med Chem; 1999 Feb 25; 42(4):659-68. PubMed ID: 10052973
    [Abstract] [Full Text] [Related]

  • 12. Dopamine/serotonin receptor ligands. Part VIII: the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testings.
    Decker M, Schleifer KJ, Nieger M, Lehmann J.
    Eur J Med Chem; 2004 Jun 25; 39(6):481-9. PubMed ID: 15183906
    [Abstract] [Full Text] [Related]

  • 13. Dopamine/serotonin receptor ligands, part III [1]: synthesis and biological activities of 7, 7'-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines -- application of the bivalent ligand approach to a novel type of dopamine receptor antagonist.
    Abadi AH, Lankow S, Hoefgen B, Decker M, Kassack MU, Lehmann J.
    Arch Pharm (Weinheim); 2002 Aug 25; 335(8):367-73. PubMed ID: 12397620
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
    Andersen K, Liljefors T, Hyttel J, Perregaard J.
    J Med Chem; 1996 Sep 13; 39(19):3723-38. PubMed ID: 8809161
    [Abstract] [Full Text] [Related]

  • 16. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA.
    J Pharmacol Exp Ther; 1995 Oct 13; 275(1):101-13. PubMed ID: 7562537
    [Abstract] [Full Text] [Related]

  • 17. 2-H- and 2-acyl-9- [omega-[4-(2-methoxyphenyl)piperazinyl]-alkyl]-1,2,3,4-tetrahydro-beta-carbolines as ligands of 5-HT1A and 5-HT2A receptors.
    Boksa J, Mokrosz MJ, Charakchieva-Minol S, Tatarczyńska E, Kłodzińska A, Wesołowska A, Misztal S.
    Pol J Pharmacol; 2001 Oct 13; 53(5):501-8. PubMed ID: 11990069
    [Abstract] [Full Text] [Related]

  • 18. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.
    J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828
    [Abstract] [Full Text] [Related]

  • 19. Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptors.
    Robaa D, Kretschmer R, Siol O, Abulazm SE, Elkhawass E, Lehmann J, Enzensperger C.
    Arch Pharm (Weinheim); 2011 Jan 01; 344(1):28-36. PubMed ID: 21213349
    [Abstract] [Full Text] [Related]

  • 20. New 1-arylindoles based serotonin 5-HT7 antagonists. Synthesis and binding evaluation studies.
    Sagnes C, Fournet G, Satala G, Bojarski AJ, Joseph B.
    Eur J Med Chem; 2014 Mar 21; 75():159-68. PubMed ID: 24531229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.